Download citation file:
The summary below is from the full report titled “Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.” It is in the 3 September 2002 issue of Annals of Internal Medicine (volume 137, pages 313-320). The authors are BR Davis, JA Cutler, CD Furberg, JT Wright Jr., MA Farber, JV Felicetta, and JD Stokes, for the ALLHAT Collaborative Research Group.
High blood pressure (hypertension) is a chronic condition that damages blood vessels and body organs. It increases the risk for heart attacks, heart failure, strokes, and kidney failure. Although the many types of drugs used to treat hypertension may reduce blood pressure by a similar amount, their ability to prevent complications of hypertension may vary. Also, different drugs cause different side effects.
Researchers showed that heart failure occurred more often in hypertensive patients taking an α-blocker (doxazosin) than a diuretic (chlorthalidone). However, the α-blocker reduced blood pressure slightly less than the diuretic. Patients taking the α-blocker also used more drugs (different types) to help reduce their blood pressure. Thus, it was difficult to sort out whether the heart failure was due to the α-blocker itself, the additional drugs, or the higher blood pressure in patients taking the α-blocker.
To compare heart failure outcomes among adults with high blood pressure who were taking a diuretic (chlorthalidone) or an α-blocker (doxazosin).
24,005 adults older than age 55 years who had high blood pressure and at least one other risk factor for heart disease (prior heart attack, stroke, diabetes, smoking, cholesterol problems, or an enlarged heart).
Patients were randomly assigned to take doxazosin or chlorthalidone. Both drugs were given once a day in the morning. Neither the patients nor their doctors knew which drug the patients received. Blood pressure was taken every 1 to 3 months. If blood pressures were higher than 140/90 mm Hg, higher drug doses and/or additional drugs (different types) were given. For the 3 years that patients were followed, researchers checked for heart failure diagnoses. They then compared the frequency of heart failure in patients assigned to doxazosin or chlorthalidone. They examined whether differences between groups could be due to differences in blood pressure or additional drugs.
Patients assigned to chlorthalidone had slightly better blood pressure control than those assigned to doxazosin. Fewer of them needed additional drugs for blood pressure control (59% vs. 68%). Heart failure occurred significantly more often in patients receiving doxazosin than in those receiving chlorthalidone, even after differences in blood pressure control and use of other drugs were considered. Risks for heart failure with doxazosin versus chlorthalidone were highest in patients receiving only those drugs and lowest in patients receiving additional drugs.
The study cannot tell us whether doxazosin caused heart failure, whether chlorthalidone prevented heart failure, or some combination of both effects.
Worse blood pressure control with doxazosin versus chlorthalidone does not explain higher heart failure risks of doxazosin. Increased risks for heart failure with doxazosin versus chlorthalidone decrease but do not disappear when other antihypertensive drugs are used.
Please read the other comments before posting. Contributors must reveal any conflict
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options
Customize your page view by dragging & repositioning the boxes below.